Basilea set for success as Toctino roll-out sees revenues surge
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceuticals is currently targeting profitability by around 2012 and has prioritised its research programmes to ensure it becomes a successful hospital and speciality products-focused company, its CEO Dr Anthony Man recently told Scrip.